The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer

Susan A. Sabatino, Trevor D. Thompson, Xiao Cheng Wu, Steven T. Fleming, Gretchen G. Kimmick, Amy Trentham-Dietz, Rosemary D Cress, Roger T. Anderson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Diabetes severity may influence breast cancer treatment choices. We examined whether receipt of guideline-concordant breast cancer treatment varied with diabetes severity. Cancer registry data from seven states regarding 6,912 stage I-III breast cancers were supplemented by medical record abstraction and physician verification. We used logistic regression models to examine associations of diabetes severity with guideline-concordant locoregional treatment, adjuvant chemotherapy, and hormonal therapy adjusted for sociodemographics, comorbidity, and tumor characteristics. We defined guideline concordance using National Comprehensive Cancer Network guidelines, and diabetes and comorbidities using the Adult Comorbidity Evaluation-27 index. After adjustment, there was significant interaction of diabetes severity with age for locoregional treatment (p = 0.001), with many diabetic women under age 70 less frequently receiving guideline-concordant treatment than non-diabetic women. Among similarly aged women, guideline concordance was lower for women with mild diabetes in their late fifties through mid-sixties, and with moderate/severe diabetes in their late forties to early sixties. Among women in their mid-seventies to early eighties, moderate/severe diabetes was associated with increased guideline concordance. For adjuvant chemotherapy, moderate/severe diabetes was less frequently associated with guideline concordance than no diabetes [OR 0.58 (95 % CI 0.36-0.94)]. Diabetes was not associated with guideline-concordant hormonal treatment (p = 0.929). Some diabetic women were less likely to receive guideline-concordant treatment for stage I-III breast cancer than non-diabetic women. Diabetes severity was associated with lower guideline concordance for locoregional treatment among middle-aged women, and lower guideline concordance for adjuvant chemotherapy. Differences were not explained by comorbidity and may contribute to potentially worse breast cancer outcomes.

Original languageEnglish (US)
Pages (from-to)199-209
Number of pages11
JournalBreast Cancer Research and Treatment
Volume146
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Guidelines
Breast Neoplasms
Comorbidity
Therapeutics
Adjuvant Chemotherapy
Logistic Models
Neoplasms
Medical Records
Registries
Physicians

Keywords

  • Breast cancer
  • Cancer treatment
  • Chemotherapy
  • Diabetes
  • Hormonal therapy
  • Radiation
  • Surgery

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sabatino, S. A., Thompson, T. D., Wu, X. C., Fleming, S. T., Kimmick, G. G., Trentham-Dietz, A., ... Anderson, R. T. (2014). The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer. Breast Cancer Research and Treatment, 146(1), 199-209. https://doi.org/10.1007/s10549-014-2998-3

The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer. / Sabatino, Susan A.; Thompson, Trevor D.; Wu, Xiao Cheng; Fleming, Steven T.; Kimmick, Gretchen G.; Trentham-Dietz, Amy; Cress, Rosemary D; Anderson, Roger T.

In: Breast Cancer Research and Treatment, Vol. 146, No. 1, 2014, p. 199-209.

Research output: Contribution to journalArticle

Sabatino, SA, Thompson, TD, Wu, XC, Fleming, ST, Kimmick, GG, Trentham-Dietz, A, Cress, RD & Anderson, RT 2014, 'The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer', Breast Cancer Research and Treatment, vol. 146, no. 1, pp. 199-209. https://doi.org/10.1007/s10549-014-2998-3
Sabatino, Susan A. ; Thompson, Trevor D. ; Wu, Xiao Cheng ; Fleming, Steven T. ; Kimmick, Gretchen G. ; Trentham-Dietz, Amy ; Cress, Rosemary D ; Anderson, Roger T. / The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer. In: Breast Cancer Research and Treatment. 2014 ; Vol. 146, No. 1. pp. 199-209.
@article{080b6aefcf9e4ba5bbab355de84eb6b5,
title = "The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer",
abstract = "Diabetes severity may influence breast cancer treatment choices. We examined whether receipt of guideline-concordant breast cancer treatment varied with diabetes severity. Cancer registry data from seven states regarding 6,912 stage I-III breast cancers were supplemented by medical record abstraction and physician verification. We used logistic regression models to examine associations of diabetes severity with guideline-concordant locoregional treatment, adjuvant chemotherapy, and hormonal therapy adjusted for sociodemographics, comorbidity, and tumor characteristics. We defined guideline concordance using National Comprehensive Cancer Network guidelines, and diabetes and comorbidities using the Adult Comorbidity Evaluation-27 index. After adjustment, there was significant interaction of diabetes severity with age for locoregional treatment (p = 0.001), with many diabetic women under age 70 less frequently receiving guideline-concordant treatment than non-diabetic women. Among similarly aged women, guideline concordance was lower for women with mild diabetes in their late fifties through mid-sixties, and with moderate/severe diabetes in their late forties to early sixties. Among women in their mid-seventies to early eighties, moderate/severe diabetes was associated with increased guideline concordance. For adjuvant chemotherapy, moderate/severe diabetes was less frequently associated with guideline concordance than no diabetes [OR 0.58 (95 {\%} CI 0.36-0.94)]. Diabetes was not associated with guideline-concordant hormonal treatment (p = 0.929). Some diabetic women were less likely to receive guideline-concordant treatment for stage I-III breast cancer than non-diabetic women. Diabetes severity was associated with lower guideline concordance for locoregional treatment among middle-aged women, and lower guideline concordance for adjuvant chemotherapy. Differences were not explained by comorbidity and may contribute to potentially worse breast cancer outcomes.",
keywords = "Breast cancer, Cancer treatment, Chemotherapy, Diabetes, Hormonal therapy, Radiation, Surgery",
author = "Sabatino, {Susan A.} and Thompson, {Trevor D.} and Wu, {Xiao Cheng} and Fleming, {Steven T.} and Kimmick, {Gretchen G.} and Amy Trentham-Dietz and Cress, {Rosemary D} and Anderson, {Roger T.}",
year = "2014",
doi = "10.1007/s10549-014-2998-3",
language = "English (US)",
volume = "146",
pages = "199--209",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer

AU - Sabatino, Susan A.

AU - Thompson, Trevor D.

AU - Wu, Xiao Cheng

AU - Fleming, Steven T.

AU - Kimmick, Gretchen G.

AU - Trentham-Dietz, Amy

AU - Cress, Rosemary D

AU - Anderson, Roger T.

PY - 2014

Y1 - 2014

N2 - Diabetes severity may influence breast cancer treatment choices. We examined whether receipt of guideline-concordant breast cancer treatment varied with diabetes severity. Cancer registry data from seven states regarding 6,912 stage I-III breast cancers were supplemented by medical record abstraction and physician verification. We used logistic regression models to examine associations of diabetes severity with guideline-concordant locoregional treatment, adjuvant chemotherapy, and hormonal therapy adjusted for sociodemographics, comorbidity, and tumor characteristics. We defined guideline concordance using National Comprehensive Cancer Network guidelines, and diabetes and comorbidities using the Adult Comorbidity Evaluation-27 index. After adjustment, there was significant interaction of diabetes severity with age for locoregional treatment (p = 0.001), with many diabetic women under age 70 less frequently receiving guideline-concordant treatment than non-diabetic women. Among similarly aged women, guideline concordance was lower for women with mild diabetes in their late fifties through mid-sixties, and with moderate/severe diabetes in their late forties to early sixties. Among women in their mid-seventies to early eighties, moderate/severe diabetes was associated with increased guideline concordance. For adjuvant chemotherapy, moderate/severe diabetes was less frequently associated with guideline concordance than no diabetes [OR 0.58 (95 % CI 0.36-0.94)]. Diabetes was not associated with guideline-concordant hormonal treatment (p = 0.929). Some diabetic women were less likely to receive guideline-concordant treatment for stage I-III breast cancer than non-diabetic women. Diabetes severity was associated with lower guideline concordance for locoregional treatment among middle-aged women, and lower guideline concordance for adjuvant chemotherapy. Differences were not explained by comorbidity and may contribute to potentially worse breast cancer outcomes.

AB - Diabetes severity may influence breast cancer treatment choices. We examined whether receipt of guideline-concordant breast cancer treatment varied with diabetes severity. Cancer registry data from seven states regarding 6,912 stage I-III breast cancers were supplemented by medical record abstraction and physician verification. We used logistic regression models to examine associations of diabetes severity with guideline-concordant locoregional treatment, adjuvant chemotherapy, and hormonal therapy adjusted for sociodemographics, comorbidity, and tumor characteristics. We defined guideline concordance using National Comprehensive Cancer Network guidelines, and diabetes and comorbidities using the Adult Comorbidity Evaluation-27 index. After adjustment, there was significant interaction of diabetes severity with age for locoregional treatment (p = 0.001), with many diabetic women under age 70 less frequently receiving guideline-concordant treatment than non-diabetic women. Among similarly aged women, guideline concordance was lower for women with mild diabetes in their late fifties through mid-sixties, and with moderate/severe diabetes in their late forties to early sixties. Among women in their mid-seventies to early eighties, moderate/severe diabetes was associated with increased guideline concordance. For adjuvant chemotherapy, moderate/severe diabetes was less frequently associated with guideline concordance than no diabetes [OR 0.58 (95 % CI 0.36-0.94)]. Diabetes was not associated with guideline-concordant hormonal treatment (p = 0.929). Some diabetic women were less likely to receive guideline-concordant treatment for stage I-III breast cancer than non-diabetic women. Diabetes severity was associated with lower guideline concordance for locoregional treatment among middle-aged women, and lower guideline concordance for adjuvant chemotherapy. Differences were not explained by comorbidity and may contribute to potentially worse breast cancer outcomes.

KW - Breast cancer

KW - Cancer treatment

KW - Chemotherapy

KW - Diabetes

KW - Hormonal therapy

KW - Radiation

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84903717934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903717934&partnerID=8YFLogxK

U2 - 10.1007/s10549-014-2998-3

DO - 10.1007/s10549-014-2998-3

M3 - Article

C2 - 24899083

AN - SCOPUS:84903717934

VL - 146

SP - 199

EP - 209

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -